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INTRODUCTION
The Federal Circuit’s In re Vivint decision considered serial inter partes
review (“IPR”) and ex parte reexamination filings, finding “the Patent
Office, when applying § 325(d), cannot deny institution of IPR based on
abusive filing practices then grant a nearly identical reexamination request
that is even more abusive.”1 However, this case was explicitly “limited,”
with the court acknowledging “there can be a public interest in
reexamination that goes beyond the interests, or propriety of behavior, of a
particular challenger.”2 And after a relatively dormant period, ex parte
reexamination has become an increasingly popular choice for challenging
patentability, including against patents already subject to IPR.3 Thus, in Parts
One and Two, this Article examines In re Vivint and, in view of that decision,
analyzes situations in which patent challengers may consider using ex parte
reexamination to challenge patents already subject to IPR. Part Three of this
Article reviews situations in which a serial reexamination challenge like that
of In re Vivint may proceed due to the “public interest.”
I. IN RE VIVINT, INC.
Vivint asserted four patents against Alarm.com in 2015.4 As part of its
defense, Alarm.com filed fourteen IPR petitions against the asserted patents,
including three serially filed petitions challenging all claims of U.S. Patent
6,717,513.5
Alarm.com filed the first petition in September of 2015.6 The Board
denied institution of IPR on the merits.7 Alarm.com filed the second petition
in November of 2015, before the first petition had been denied, presenting
grounds based on different references.8 The Board again denied institution,
this time because it found the primary reference relied on in all of the grounds
did not qualify as prior art.9 Alarm.com filed the third petition (the ‘091

1. In re Vivint, Inc., 14 F.4th 1342, 1354 (Fed. Cir. 2021); 35 U.S.C. § 325(d) (Sept. 16, 2012)
(stating “[i]n determining whether to institute or order a proceeding under this chapter, chapter 30, or
chapter 31, the Director may take into account whether, and reject the petition or request because, the
same or substantially the same prior art or arguments previously were presented to the Office”).
2. Vivint, 14 F.4th at 1354 (emphasis in original).
3. Reexamination Operational Statistics, UNITED STATES PATENT AND TRADEMARK OFFICE,
https://www.uspto.gov/sites/default/files/documents/reexamination-op-stats-FY22Q1.pdf
[https://perma.cc/NB3X-PQYM] (showing an increase in ex parte reexamination request filings from
2019 to 2021); David Cavanaugh et al., Potential Changes to PTAB Practice On Multiple IPR Petitions,
BLOOMBERG L. PROF. PERSP., Nov. 2019, at 5.
4. Vivint, 14 F.4th at 1346.
5. Id.
6. Alarm.com Inc. v. Vivint, Inc., No. IPR2015-01997, Paper 1 (P.T.A.B. Sept. 28, 2015);
Alarm.com Inc. v. Vivint, Inc., No. IPR2015-01997, Paper 14 at 8–9 (P.T.A.B. April 7, 2016).
7. Alarm.com Inc. v. Vivint, Inc., IPR2015-01997, Paper 14 at 29–31 (P.T.A.B. April 7, 2016).
8. Alarm.com Inc. v. Vivint, Inc., No. IPR2016-00129, Paper 1 (P.T.A.B. Nov. 2, 2015);
Alarm.com Inc. v. Vivint, Inc., No. IPR2016-00129, Paper 13 at 9 (P.T.A.B. May 3, 2016).
9. Alarm.com Inc. v. Vivint, Inc., No. IPR2016-00129, Paper 13 at 16–17 (P.T.A.B. May 3, 2016).
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petition) in May of 2016, after the first two petitions had been denied,
presenting grounds including combinations of references from the prior
petitions.10 Here, the Board exercised discretion under 35 U.S.C. § 314(a)11
to deny institution of IPR, finding Alarm.com used the Board’s “decisions
in the earlier cases as a roadmap for attempts to remedy deficiencies in its
earlier petitions” and that the filing constituted “undesirable, incremental
petitioning.”12
Alarm.com then requested ex parte reexamination of all claims in
August of 2017, over a year after discretionary denial of the ‘091 petition,
where Alarm.com raised four substantial new questions of patentability
(“SNQs”), with two of the questions overlapping grounds in the ‘091
petition.13 The United States Patent and Trademark Office (“USPTO”)
ordered reexamination on all SNQs.14 Vivint petitioned the Patent Office
under 37 C.F.R. § 1.181 twice during the reexamination—first seeking
dismissal under 35 U.S.C. § 325(d) by arguing the Patent Office “could not
decline to institute IPR based on abusive filing practices, yet grant
reexamination on essentially the same facts,” and after that petition was
denied, petitioning again seeking reconsideration of the Section 325(d)
issue.15 But the Patent Office denied the second petition too, and a final
rejection eventually issued rejecting all claims.16 Vivint appealed the final
rejection to the Patent Trial and Appeal Board (“PTAB”), which affirmed
but did not address Section 325(d), and Vivint thereafter appealed to the
Federal Circuit.17
On appeal, Vivint asserted Alarm.com’s ex parte reexamination request
did not present any SNQs under 35 U.S.C. § 303(a) because the questions
“‘had already been considered and rejected by the Board’ in the ‘091
10. Alarm.com Inc. v. Vivint, Inc., No. IPR2016-01091, Paper 1 (P.T.A.B. May 24, 2016);
Alarm.com Inc. v. Vivint, Inc., IPR2016-01091, Paper 11 at 5 (P.T.A.B. Nov. 23, 2016).
11. 35 U.S.C. § 314(a) states “[t]he Director may not authorize an inter partes review to be instituted
unless the Director determines that the information presented in the petition filed under section 311 and
any response filed under section 313 shows that there is a reasonable likelihood that the petitioner would
prevail with respect to at least 1 of the claims challenged in the petition.”
12. Alarm.com Inc. v. Vivint, Inc., IPR2016-01091, Paper 11 at 10, 12, 14 (P.T.A.B. Nov. 23,
2016).
13. Vivint, 14 F.4th at 1346–48 (the court noted the request “repackaged the arguments raised in the
‘091 petition” that had been denied and “vast swaths of the ex parte reexamination request copied, almost
word for word, the ‘091 petition”); Ex Parte Reexamination Control No. 90/020,115, Reexamination
Request.
14. Vivint, 14 F.4th.at 1346–48; Ex Parte Reexamination Control No. 90/020,115, Decision
Granting Ex Parte Reexamination.
15. Vivint, 14 F.4th. at 1347-48.
16. Id.; 37 C.F.R. § 1.181 (Sept. 16, 2012) (stating “(a) Petition may be taken to the Director:
(1) From any action or requirement of any examiner in the ex parte prosecution of an application, or in
ex parte or inter partes prosecution of a reexamination proceeding which is not subject to appeal to the
Patent Trial and Appeal Board or to the court; (2) In cases in which a statute or the rules specify that the
matter is to be determined directly by or reviewed by the Director; and (3) To invoke the supervisory
authority of the Director in appropriate circumstances. For petitions involving action of the Patent Trial
and Appeal Board, see § 41.3 of this title”); 35 U.S.C. § 325(d) (Sept. 16, 2012).
17. Vivint, 14 F.4th at 1347–48.
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Decision.”18 The court disagreed, noting only two questions raised by the
request overlapped with grounds of the ‘091 petition.19 The court further
explained “a question of patentability is new until it has been considered and
decided on the merits,” and in the ‘091 petition’s proceeding, the PTAB had
not decided questions of patentability because it instead exercised discretion
to deny institution based on “abusive filing practices.”20
Vivint also contended the USPTO “abused its discretion and acted
arbitrarily and capriciously by ordering reexamination, and thereafter,
refusing to terminate that proceeding”21 in view of § 325(d). The court
agreed, finding the USPTO’s Section 325(d) determination should be set
aside.22 The court further explained that while it would normally vacate the
Patent Office’s decision in view of its findings, “it would be arbitrary and
capricious for the Patent Office to do anything on remand other than
terminate the reexamination.”23 The ‘091 petition’s institution decision
“focused on Alarm.com’s abusive filing practices” and how it was
“undesirable, incremental petitioning,” and while the PTAB applied Section
314(a) to deny institution, “it actually relied on [Section] 325(d)
considerations for its core analysis,” examining “whether the Petitioner’s
current challenges present the same or substantially the same art or
arguments as those previously presented to the Office.”24 Thus, the
reexamination request was an even “more egregious abuse than the ‘091
petition under the same considerations already analyzed by the Board”
because it “was another, fourth iteration of Alarm.com’s abuse of process”
that “copied, word-for-word, two grounds from the ‘091 petition—the very
petition deemed a ‘case of undesirable, incremental petitioning,’” and the
non-copied portions “‘used prior Board decisions as a roadmap to correct
past deficiencies.’”25 The court explained “the Patent Office, when
applying Section 325(d), cannot deny institution of IPR based on abusive
filing practices then grant a nearly identical reexamination request that is
even more abusive,” and “[w]e see no difference between the IPR and ex

18. Id. at 1348–50; see 35 U.S.C. § 303 (a) (stating “[w]ithin three months following the filing of a
request for reexamination under the provisions of section 302, the Director will determine whether a
substantial new question of patentability affecting any claim of the patent concerned is raised by the
request, with or without consideration of other patents or printed publications”).
19. Vivint, 14 F.4th at 1350.
20. Id. at 1347.
21. Id. at 1350.
22. Id. at 1350–52. The court explained it was “legal error” for the USPTO to narrowly interpret its
authority to reconsider orders granting reexamination, and “arbitrary and capricious for it to order
reexamination over § 325(d), or at a minimum, refuse to terminate reexamination once Vivint requested
it do so.”
23. Id. at 1352; see also id. at 1353 (“it was unreasonable for the Patent Office to order
reexamination, and once ordered, to refuse to terminate it”).
24. Id. at 1352–53.
25. Id. at 1353.
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parte reexamination processes that would justify such conduct and nothing
short of termination of the reexamination would be appropriate.”26
The court finally noted its ruling was “limited” because “there can be
a public interest in reexamination that goes beyond the interests, or propriety of
behavior, of a particular challenger,” which is reflected by the Director’s authority
to launch an ex parte reexamination “[o]n his own initiative.”27

II. USING EX PARTE REEXAMINATION TO CHALLENGE PATENTS ALREADY
SUBJECT TO INTER PARTES REVIEW
After In re Vivint, patent challengers should consider whether ex parte
reexamination is an appropriate option in view of Sections 303(a) and 325(d)
if one or more IPRs have already been filed. 35 U.S.C. § 315(d) should also
be considered since it addresses the Director’s options when multiple
proceedings involving the same patent are pending before the Office.28 This
part of the Article reviews potential situations challengers may face and the
analysis they should undertake to decide whether to file.
A. Filing a Reexamination Request Before Institution Decisions are
Rendered
If a reexamination request is filed when IPRs challenging the same
patent are pending before institution, the PTAB has not yet considered the
merits in the IPRs, so whether the same or different art and/or arguments are
26. Id. at 1354 (explaining “§ 325(d) applies to both IPR petitions and requests for ex
parte reexamination”).
27. Vivint, 14 F.4th at 1354. (emphasis in original), citing 35 U.S.C. § 303(a) (Sept. 16, 2012)
(which states “[o]n his own initiative, and any time, the Director may determine whether a substantial
new question of patentability is raised by patents and publications discovered by him or cited under the
provisions of section 301 or 302”) and 37 C.F.R. § 1.520 (which states “[t]he Director, at any time during
the period of enforceability of a patent, may determine whether or not a substantial new question of
patentability is raised by patents or printed publications which have been discovered by the Director or
which have been brought to the Director’s attention, even though no request for reexamination has been
filed in accordance with § 1.510 or § 1.913”). The court further explained “we are not holding that the
Director may never launch a reexamination even when a particular challenger has engaged in improper
serial filing.” Vivint, 14 F.4th at 1354.
28. 35 U.S.C. § 315(d) (Sept. 16, 2012) (stating “Notwithstanding sections 135(a), 251, and 252,
and chapter 30, during the pendency of an inter partes review, if another proceeding or matter involving
the patent is before the Office, the Director may determine the manner in which the inter partes review or
other proceeding or matter may proceed, including providing for stay, transfer, consolidation, or
termination of any such matter or proceeding”); see Notice Regarding Options for Amendments by Patent
Owner Through Reissue or Reexamination During a Pending AIA Trial Proceeding, 84 Fed. Reg. 16,654,
16,657 (Apr. 22, 2019) (listing several factors that are considered when deciding whether to stay a
reexamination involving the same patent at issue in an IPR under § 315(d), including (1) whether the
claims challenged in the AIA proceeding are the same as or depend directly or indirectly from claims at
issue in the concurrent parallel Office proceeding, (2) whether the same grounds of unpatentability or the
same prior art are at issue in both proceedings, (3) whether the concurrent parallel Office proceeding will
duplicate efforts within the Office, (4) whether the concurrent parallel Office proceeding could result in
inconsistent results between proceedings (e.g., whether substantially similar issues are presented in the
concurrent parallel Office proceeding), (5) whether amending the claim scope in one proceeding would
affect the claim scope in another proceeding, (6) the respective timeline and stage of each proceeding, (7)
the statutory deadlines of the respective proceedings, and (8) whether a decision in one proceeding would
likely simplify issues in the concurrent parallel Office proceeding or render it moot).
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included in the request, the reexamination would still likely present SNQs
under § 303(a) if the central reexamination unit reviews the request before
the PTAB renders an institution decision.29 Although the challenger could
not be accused of using any PTAB decision as a “roadmap” due to a decision
not yet being rendered, if art and/or arguments overlap between the request
and IPRs, the reexamination may still be denied due to § 325(d); here,
analyzing the Becton, Dickenson factors may be helpful.30 In the present
example, the “same or substantially the same prior art or arguments” would
have already been “presented” to the office in the IPR. Under Becton,
Dickenson, the similarity of art, cumulative nature of art, and/or overlap of
arguments (factors (a), (b), and/or (d)) would likely cut against a requester
even though the extent of the prior art analysis (factor (c)) would be
inapplicable since an institution decision had not yet issued.31 A challenger
should also consider § 315(d) in this example because multiple proceedings
would be “before the Office” and the Director would have the ability to
terminate or stay one of them.32
The risk of denial may decrease if a reexamination request uses
different, non-cumulative art and/or arguments because, in addition to the
lack of a “roadmap” from the IPRs, factors (a), (b), and/or (d) would not be
as relevant, and SNQs under § 303(a) would likely be found as the invalidity
grounds would not have been considered yet by the PTAB.33 However, the

29. Vivint, 14 F.4th at 1348–50.
30. Id. at 1353. When evaluating whether to institute an IPR in view of Section 325(d), the PTAB
examines the non-exclusive Becton, Dickenson factors. Becton, Dickenson & Co. v. B. Braun Melsungen
AG, No. IPR2017-01586, Paper 8 at 17–18 (P.T.A.B. Dec. 15, 2017) (precedential as to section III.C.5,
first paragraph). The Becton, Dickenson factors include (a) the similarities and material differences
between the asserted art and the prior art involved during examination; (b) the cumulative nature of the
asserted art and the prior art evaluated during examination; (c) the extent to which the asserted art was
evaluated during examination, including whether the prior art was the basis for rejection; (d) the extent
of the overlap between the arguments made during examination and the manner in which Petitioner relies
on the prior art or Patent Owner distinguishes the prior art; (e) whether Petitioner has pointed out
sufficiently how the Examiner erred in its evaluation of the asserted prior art; and (f) the extent to which
additional evidence and facts presented in the Petition warrant reconsideration of the prior art or
arguments. Id.; see also Advanced Bionics, which explains “[t]he factors set forth in Becton, Dickinson
should be read broadly, however, to apply to any situation in which a petition relies on the same or
substantially the same art or arguments previously presented to the Office during a proceeding pertaining
to the challenged patent.” Advanced Bionics, LLC v. MED-EL Elektromedizinische Ger. . .te GmbH,
No. IPR2019-01469, Paper 6 at 9–10 (P.T.A.B. Feb. 13, 2020) (precedential). In the reexamination
context, the Trial Practice Guide explains that “the Office may not necessarily consider these factors”
when deciding whether to order reexamination as “[a]n ex parte reexamination proceeding is not a trial
proceeding, and the considerations with respect to issues involving 35 U.S.C. § 325(d) may differ due to
the different nature of an ex parte reexamination proceeding.” Patent Trial and Appeal Board
Consolidated Trial Practice Guide (Nov. 2019), UNITED STATES PATENT AND TRADEMARK OFFICE, 63,
https://www.uspto.gov/sites/default/files/documents/tpgnov.pdf?MURL=
[https://perma.cc/BS34WS4T]. But in view of In re Vivint’s focus on previously presented art and arguments under 325(d) in
the reexamination context, analyzing the Becton, Dickenson factors may be a helpful exercise.
31. Becton, Dickenson & Co. v. B. Braun Melsungen AG, No. IPR2017-01586, Paper 8 at 17–18
(P.T.A.B. Dec. 15, 2017) (precedential as to section III.C.5, first paragraph).
32. 35 U.S.C. § 315(d).
33. See supra note 30; see supra note 18.
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Director may still terminate or stay the later filed reexamination under §
315(d) due to the multiple pending proceedings.34
If all prior IPRs were terminated before institution—for example, due
to settlement between the parties—and a subsequent reexamination request
was filed against the patent, the risk of denial may also decrease. Regardless
of whether the same or substantially the same art and/or arguments were
presented in the reexamination relative to the IPRs, the PTAB would not be
examining the merits of those arguments or otherwise have provided a
“roadmap” for the subsequent challenger.35 Thus, SNQs would likely be
present and the risk of denial under § 325(d) for abusive filing practices may
be limited because this would not be a case of “incremental” challenging that
uses any prior decision as roadmap.36 Under Becton, Dickenson, if art and/or
arguments are the same between the IPRs and reexamination, factors (a), (b),
and/or (d) may cut against a requester, but the extent of the prior art analysis
(factor (c)) would be inapplicable.37 Moreover, multiple proceedings would
not be pending before the Office, eliminating the risk of termination or stay
under § 315(d).38
B. Filing a Reexamination Request After Institution Decisions are
Rendered
After institution decisions have issued, the risk of a subsequently filed
reexamination request being denied under § 325(d) may increase because the
decisions can be used as a “roadmap” for a requester.39 Whether art and/or
arguments of the reexamination request are new or overlap with that in the
IPRs, reexamination may be denied because it could be considered
incremental challenging.40
If art and/or arguments do overlap between filed IPRs and
reexamination, and if institution was granted in the IPRs, an elevated risk of
the reexamination being denied due to Sections 303(a) and 325(d) likely
exists. In view of Section 303(a), the Office may find that SNQs do not exist
because the art or arguments have already been considered by the PTAB at
institution; in view of Section 325(d), the “same or substantially the same
prior art or arguments” would have already been “presented” to the office in
the IPR and analyzed by the PTAB, providing a roadmap, and under Becton,
Dickenson, similarity of art, cumulative nature of art, and/or overlap of
arguments (factors (a), (b), and/or (d)) would likely cut against a requester,
as well as the extent of the prior art analysis (factor (c)) since an institution
34.
35.
36.
37.
38.
39.
40.

See supra note 32.
Vivint, 14 F.4th at 1348–50, 1353.
Id.
See supra note 30.
See supra note 32.
Vivint, 14 F.4th at 1353.
Id.
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decision issued.41 Under § 315(d), multiple proceedings would be “before
the Office” and the Director would have the ability to terminate or stay one
of them under § 315(d), likely the reexamination due to the IPRs being at a
more advanced, post-institution stage.42
If IPR(s) are terminated after institution—again, for example, due to
settlement—and a reexamination request is subsequently filed, multiple
proceedings would not be pending in parallel before the Office, removing §
315(d) issues.43 But if the “same or substantially the same” art and/or
arguments as the IPR is presented in the reexamination, a denial risk may
exist under § 303(a), because the SNQs would have already been considered
(albeit positively) by the PTAB, and under § 325(d) because the serially filed
request could be seen as engaging in “harassment of patent owners and
frustration of Congress’ intent in enacting the [AIA]” and under Becton,
Dickenson, the same factors discussed in the previous post-institution
example would apply.44 However, the relevant § 325(d) analysis of In re
Vivant rested on the “same petitioner” filing the serial reexamination.45 An
unrelated entity filing its first challenge against the patent via the
reexamination request may not be subject to the § 325(d) issues of In re
Vivant because they have not engaged in any serial or abusive filing
practices. And the grounds of the petition would have been preliminarily
approved by the PTAB because it instituted trial, indicating likely success
before the central reexamination unit; if the reexamination request raised
SNQs corresponding to the instituted IPR grounds, but explained how they
were different, included additional explanation, or were enhanced in some
way, the Patent Office may allow it to proceed under § 303(a).46
If a challenger’s IPR results in a final written decision, that same
challenger would be estopped from filing an ex parte reexamination under §
315(e)(1) with respect to a claim on any ground the petitioner raised or
reasonably could have raised in the IPR.47 An unrelated entity would be free

41. See supra note 30; see supra note 18.
42. 35 U.S.C. § 315(d); see supra note 3.
43. Id.
44. Vivint, 14 F.4th at 1353 (quoting Alarm.com, No. IPR2016-01091, Paper 11 at 12); see supra
note 30.
45. Id.
46. 35 U.S.C. § 314(a) (Sept. 16, 2012); see supra, note 18.
47. 35 U.S.C. § 315(e)(1) (Sept. 16, 2012); UNITED STATES PATENT AND TRADEMARK OFFICE,
MANUAL OF PATENT EXAMINING PROCEDURE § 2212 (9th ed. rev. Oct. 2019, June 2020) (explaining
“[t]he only “person” who is barred from filing a request for ex parte reexamination of a patent under 35
U.S.C. § 302 is one who is barred from doing so by the estoppel provisions of AIA, 35 U.S.C. [§]
315(e)(1) or 35 U.S.C. [§] 325(e)(1) based on inter partes review and post grant review, respectively,
once the estoppel attaches”). Note that since a challenger does not participate in ex parte reexamination
after it is ordered, the Section 315(e)(1) preclusion of a challenger “maintain[ing] a proceeding before the
Office with respect to that claim on any ground that the petitioner raised or reasonably could have raised
during that inter partes review” does not apply to a pending reexamination that addresses the same
claim(s) of a prior IPR that has an issued final written decision. 35 U.S.C. § 315(e)(1) (Sept. 16, 2012).
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to challenge the patent via reexamination, but §§ 303(a), 315(d), and 325(d)
as discussed above should be considered.
III. SITUATIONS WHERE A SERIAL REEXAMINATION CHALLENGE MAY
PROCEED DUE TO THE “PUBLIC INTEREST”
In re Vivant explains “there can be a public interest in reexamination
that goes beyond the interests, or propriety of behavior, of a particular
challenger,” which is “reflected most expressly in the statute’s grant to the
Director of the authority to launch an ex parte reexamination ‘[o]n his own
initiative.’”48 When Director initiated reexamination has occurred, it has
been due to a “compelling reason” from the Office’s perspective, such as a
significantly large damages award in district court litigation,49 patent
assertion implicating non-technical human behavior,50 or questionable patent
examination practices.51 Thus, it follows that reexamination requests filed
against patents that have been previously subject to IPRs may be allowed to
proceed if the public interest is similarly impacted.
One exemplary situation where the public interest may compel a
serially filed reexamination to proceed is when IPRs have been denied
without an examination of the merits and a district court grants a substantial
damages award in related litigation for the patent at issue.52 This situation
mirrors the Director initiated review of U.S. Patent 5,838,906, which had an

48. Vivint, 14 F.4th at 1354 (emphasis in original); 37 C.F.R. § 1.520 (Dec. 7, 2000). Director
initiated reexamination is rare. See Ex Parte Reexamination Filing Data – September 30, 2020, UNITED
STATES
PATENT
AND
TRADEMARK
OFFICE,
https://www.uspto.gov/sites/default/files/documents/ex_parte_historical_stats_roll_up_21Q1.pdf
[https://perma.cc/KF7M-CUCU](showing that as of September 30, 2020, only 1.2% (175 total) of
reexamination requests have been filed by the Director since July 1981).
49. See Ex Parte Reexamination Control No. 90/006,831, challenging U.S. Patent 5,838,906,
Reexamination Request at 2. The ‘906 patent had an associated damages award of $521 million in district
court. See Amy L. Magas, When Politics Interfere with Patent Reexamination, 4 J. MARSHALL REV.
INTELL. PROP. L. 160, 169–170 (2004).
50. See Ex Parte Reexamination Control No. 90/006,868, challenging U.S. Patent 6,567,790. In
district court, Wealth Transfer Group, LLC asserted the’790 patent against Dr. John W. Rowe, the
President and CEO of Aetna U.S. Healthcare, alleging Dr. Rowe’s advisors had funded two trusts with
nonqualified stock options that infringed the patent. Tax Strategies? INSURANCE IP BULLETIN, Oct. 15,
2006,
available
at
http://www.bakosenterprises.com/IP/B-10152006/IPB-10152006.html
[https://perma.cc/3XRE-43RL].
51. See Director-initiated Ex Parte Reexamination Control No. 90/006,289, challenging U.S. Patent
6,368,227 titled “Method for Swinging on a Swing;” Director-initiated Ex Parte Reexamination Control
No. 90/006,068, challenging U.S. Patent 6,022,219 titled “Painting Kit and Related Method” and reciting
in claim 1 “[a] method of painting on a work surface using the posterior of an infant,” where the method
included “stamping the posterior on said background media to create stamping prints.”
52. See, e.g., Intel Corp. v. VLSI Tech. LLC, No. IPR2020-00106, Paper 17 at 4–13 (P.T.A.B. May
5, 2020), Intel Corp. v. VLSI Tech. LLC, No. IPR2020-00158, Paper 16 at 4–14 (P.T.A.B. May 20, 2020),
Intel Corp. v. VLSI Tech. LLC, No. IPR2020-00498, Paper 16 at 4–10 (P.T.A.B. Aug. 19, 2020) (denying
institution due to discretionary factors without an examination of the merits, where the district court in
related litigation awarded $2.18 billion in damages associated with patents); Alan Cox, The Damages
Testimony
in
VLSI
Technologies
v.
Intel,
PATENTLYO
(Mar.
19,
2021),
https://patentlyo.com/patent/2021/03/damages-testimony-technologies.html
[https://perma.cc/9QZ4Y7SG].
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associated damages award of $521 million.53 The USPTO may deem that a
serial challenge should not be terminated to ensure a significant damages
award is not premised on invalid claims.54
Another exemplary situation in which the public interest may allow
serially filed reexamination to proceed involves national security. Huawei,
which has close ties to the Chinese state, is a leading patent holder in 5G
technologies, but has been excluded from selling much of its smartphone and
5G infrastructure equipment in the U.S. due to cyber-security and IP theft
concerns.55 In response, Huawei resorted to patent assertion campaigns in
the U.S. to create revenue streams that replaced lost equipment sales due to
the exclusion.56 This type of practice poses a national security threat because,
in addition to circumventing the intended effect of the exclusion, it has the
potential to flood U.S. courts with new patent cases and drain resources from
targeted U.S. companies, stifling domestic innovation.57 Thus, when patents
are asserted against U.S. companies in this manner by such state-linked
entities, and ensuing IPRs fail, the USPTO may consider allowing serially
filed reexaminations to proceed to combat this threat.58
CONCLUSION
After In re Vivint, when IPRs have already been filed but a further
challenge is desirable, challengers should carefully consider whether ex
parte reexamination is a viable option. Challengers should also consider
whether the public interest would weigh in favor of reexamination.

53. See supra note 49.
54. See supra note 49; supra note 52.
55. Jonathan Stroud & Levi Lall, Paper of Record: Modernizing Ownership Disclosures for U.S.
Patents (July 12, 2021) at 1, 3–7, 12–15, 19–23, W. VA. L. REV., forthcoming, available at
SSRN: https://ssrn.com/abstract=3885076 [https://perma.cc/GLS5-XSMG]; Tim Pohlmann, Who is
leading the 5G patent race? A patent landscape analysis on declared SEPs and standards contributions,
IAM (Feb. 17, 2021), https://www.iam-media.com/who-leading-the-5g-patent-race-patent-landscapeanalysis-declared-seps-and-standards-contributions [https://perma.cc/J8HW-RATD].
56. Id., 15, 21–23.
57. See supra note 55.
58. Id.

